ConforMIS released results from several clinical research studies highlighting the benefits of the iTotal patient-specific total knee replacement. Results were shown at the
According to a release, the iTotal system, a patient-specific total knee replacement system on the market, demonstrated zero blood transfusions and positive clinical outcomes. A recent
The Company said that 100 percent of patients reported a normal feeling knee only seven months after the procedure. This is in contrast to high dissatisfaction rates reported in the literature, ranging from 15 percent to 39 percent of knee replacement patients with standard, off-the-shelf implants.
"We are very pleased to see further clinical evidence showing that the ConforMIS patient-specific technology is not only helping surgeons to improve patient outcomes with knee replacements, but the technology is also contributing meaningful cost savings to the healthcare system," said
ConforMIS clinical results presented at BASK include:
-"Early Outcomes Utilizing a First-Generation Customized Patient- Specific TKA Implant" (P0185). Lead researcher
-"Intraoperative Assessment of Mechanical Alignment Accuracy Determined by Computer Navigation in a Patient-Specific TKA (Total Knee Arthroplasty) System" (Session 6). Data presented by
-"In Vivo Tibial Fit Analysis of Customized, Patient-Specific TKA Versus Off-the-Shelf TKA" (P0181). Data demonstrated that use of iTotal significantly improves tibial fit when compared to off-the- shelf TKA implants. The study concluded, "this could play an important role in reducing knee pain and patient dissatisfaction ... as well as implant loosening."
ConforMIS is a privately-held medical device company.
((Comments on this story may be sent to email@example.com))
ConforMIS released results from several clinical research studies highlighting the benefits of the iTotal patient-specific total knee replacement.
Results were shown at the